Distinct HLA class I and II genotypes and haplotypes are associated with multiple sclerosis in Bahrain

Al-Nashmi,Moudi; Taha,Safa; Salem,Abdel  Halim; Alsharoqi,Isa; Bakhiet,Moiz

doi:10.3892/br.2018.1164

Distinct HLA class I and II genotypes and haplotypes are associated with multiple sclerosis in Bahrain

Authors:
- Moudi Al-Nashmi
- Safa Taha
- Abdel Halim Salem
- Isa Alsharoqi
- Moiz Bakhiet
View Affiliations

Affiliations: Department of Molecular Medicine, Princess Al-Jawhara Center for Genetics and Inherited Diseases, Arabian Gulf University, Manama 329, Bahrain, Department of Anatomy, College of Medicine and Medical Sciences, Arabian Gulf University, Manama 329, Bahrain, Department of Neuroscience, Salmaniya Medical Complex, Manama 12, Bahrain
Published online on: October 24, 2018 https://doi.org/10.3892/br.2018.1164
Pages: 531-539

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple sclerosis (MS) has become prevalent in the Arabian Gulf area with high incidence in Bahrain due to environmental influences and genetic susceptibilities, but there is a lack of study into human leukocyte antigen (HLA) types in patients with MS in Bahrain. The present study aimed to study the HLA types expressed in MS patients compared with in control subjects. Blood samples from 50 Bahraini patients with MS and 50 Bahraini control subjects' were subjected to HLA tissue typing by polymerase chain reaction using sequence-specific primers. In comparison with those in control subjects, the allele frequencies of HLA class-I antigens A2, A9, A19, B5, B35 and B40 were higher in MS patients. For class II antigens, the allele frequencies of DR3, DR4 and DR16 were higher in MS patients. The allele frequency of DR15 was lower in MS patients than in control subjects but the difference was not statistically significant (P=0.138). The higher prevalence of the HLA-ABDR allele was common among the female patients with MS, in relapse remission stage, in cases with higher expanded disability status scale scores and with disease duration between 4 and 9 years. Haplotype HLA-A2-B40-DR2 exhibited significantly higher frequency in MS patients compared with in control subjects (P=0.03). In conclusion, the results indicated different alleles associated with MS compared with previous reviews. The present study supports the importance of identifying genetic susceptibilities and targets for therapies in specific populations and individuals, to personalize disease management in terms of prediction, protective measures and treatment.

View Figures

View References

1	Rhead B, Bäärnhielm M, Gianfrancesco M, Mok A, Shao X, Quach H, Shen L, Schaefer C, Link J, Gyllenberg A, et al: Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurol Genet. 2:e972016. View Article : Google Scholar : PubMed/NCBI
2	Sahraian MA, Sahebkar M, Dehghani R, Derakhshan-Jazari M, Kazami-Moghaddam V and Kouchaki E: Multiple sclerosis-A disease on a dramatically rising trend in Iran: Review of possible reasons. Iran J Neurol. 16:34–40. 2017.PubMed/NCBI
3	Dargahi N, Katsara M, Tselios T, Androutsou ME, de Courten M, Matsoukas J and Apostolopoulos V: Multiple sclerosis: Immunopathology and treatment update. Brain Sci. 7:E782017. View Article : Google Scholar : PubMed/NCBI
4	Harbo HF, Gold R and Tintoré M: Sex and gender issues in multiple sclerosis. Ther Adv Neurol Disorder. 6:237–248. 2013. View Article : Google Scholar
5	Johnson KM, Zhou H, Lin F, Ko JJ and Herrera V: Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. J Manag Care Spec Pharm. 23:844–852. 2017.PubMed/NCBI
6	Mescheriakova JY, Broer L, Wahedi S, Uitterlinden AG, van Duijn CM and Hintzen RQ: Burden of genetic risk variants in multiple sclerosis families in the Netherlands. Mult Scler J Exp Transl Clin. 2:20552173166487212016.PubMed/NCBI
7	Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, Vyse TJ and Rioux JD: Defining the role of the MHC in autoimmunity: A review and pooled analysis. PLoS Genet. 4:e10000242008. View Article : Google Scholar : PubMed/NCBI
8	Moutsianas L, Jostins L, Beecham AH, Dilthey AT, Xifara DK, Ban M, Shah TS, Patsopoulos NA, Alfredsson L, Anderson CA, et al; International IBD Genetics Consortium (IIBDGC), . Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat Genet. 47:1107–1113. 2015. View Article : Google Scholar : PubMed/NCBI
9	Parnell GP and Booth DR: The multiple sclerosis (MS) genetic risk factors indicate both acquired and innate immune cell subsets contribute to MS pathogenesis and identify novel therapeutic opportunities. Front Immunol. 8:4252017. View Article : Google Scholar : PubMed/NCBI
10	Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, et al: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 69:292–302. 2011. View Article : Google Scholar : PubMed/NCBI
11	Institute of Medicine (US) Committee on Multiple Sclerosis: Current Status and Strategies for the Future. Multiple Sclerosis. Joy JE and Johnston RB Jr: National Academies Press; Washington, DC: 2001
12	Moosazadeh M, Esmaeili R, Mehdi Nasehi M, Abedi G, Afshari M, Farshidi F and Kheradmand M: Prevalence of familial multiple sclerosis in Iran: A systematic review and meta-analysis. Iran J Neurol. 16:90–95. 2017.PubMed/NCBI
13	Deleu D, Mir D, Al Tabouki A, Mesraoua R, Mesraoua B, Akhtar N, Al Hail H, D'souza A, Melikyan G, Imam YZ, et al: Prevalence, demographics and clinical characteristics of multiple sclerosis in Qatar. Mult Scler. 19:816–819. 2013. View Article : Google Scholar : PubMed/NCBI
14	Link J, Lundkvist Ryner M, Fink K, Hermanrud C, Lima I, Brynedal B, Kockum I, Hillert J and Fogdell-Hahn A: Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis. PLoS One. 9:e904792014. View Article : Google Scholar : PubMed/NCBI
15	Hebbring SJ, Schrodi SJ, Ye Z, Zhou Z, Page D and Brilliant MH: A PheWAS approach in studying HLA-DRB1*1501. Genes Immun. 14:187–191. 2013. View Article : Google Scholar : PubMed/NCBI
16	Anagnostouli MC, Acquaviva T, Artemiadis AK, Rentzos M, Karandreas N, Davaki P and Stamboulis E: HLA-DRB1* alleles genotyping in chronic inflammatory demyelinating polyneuropathy in Greek patients. J Peripher Nerv Syst. 19:187–189. 2014. View Article : Google Scholar : PubMed/NCBI
17	Cocco E, Sardu C, Pieroni E, Valentini M, Murru R, Costa G, Tranquilli S, Frau J, Coghe G, Carboni N, et al: HLA-DRB1-DQB1 haplotypes confer susceptibility and resistance to multiple sclerosis in Sardinia. PLoS One. 7:e339722012. View Article : Google Scholar : PubMed/NCBI
18	Healy BC, Liguori M, Tran D, Chitnis T, Glanz B, Wolfish C, Gauthier S, Buckle G, Houtchens M, Stazzone L, et al: HLA B*44: Protective effects in MS susceptibility and MRI outcome measures. Neurology. 75:634–640. 2010. View Article : Google Scholar : PubMed/NCBI
19	Alcina A, Abad-Grau MM, Fedetz M, Izquierdo G, Lucas M, Fernández O, Ndagire D, Catalá-Rabasa A, Ruiz A, Gayán J, et al: Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations. PLoS One. 7:e298192012. View Article : Google Scholar : PubMed/NCBI
20	Patsopoulos NA, Barcellos LF, Hintzen RQ, Schaefer C, van Duijn CM, Noble JA, Raj T, Gourraud PA, Stranger BE, Oksenberg J, et al; IMSGC; ANZgene, . Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet. 9:e10039262013. View Article : Google Scholar : PubMed/NCBI
21	Al-Shammri S, Nelson RF, Al-Muzairi I and Akanji AO: HLA determinants of susceptibility to multiple sclerosis in an Arabian Gulf population. Mult Scler. 10:381–386. 2004. View Article : Google Scholar : PubMed/NCBI
22	Chao MJ, Barnardo MC, Lincoln MR, Ramagopalan SV, Herrera BM, Dyment DA, Montpetit A, Sadovnick AD, Knight JC and Ebers GC: HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc Natl Acad Sci USA. 105:13069–13074. 2008. View Article : Google Scholar : PubMed/NCBI
23	Link J, Kockum I, Lorentzen AR, Lie BA, Celius EG, Westerlind H, Schaffer M, Alfredsson L, Olsson T, Brynedal B, et al: Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis. PLoS One. 7:e367792012. View Article : Google Scholar : PubMed/NCBI
24	Kalanie H, Kamgooyan M, Sadeghian H and Kalanie AR: Histocompatibility antigen (HLA) associations with multiple sclerosis in Iran. Mult Scler. 6:317–319. 2000. View Article : Google Scholar : PubMed/NCBI
25	Smagina IV, El'chaninova SA, Zolovkina AG, Ignatova IuN and Kudriavtseva EA: Genetic risk factors for multiple sclerosis in the population of Altay. Zh Nevrol Psikhiatr Im S S Korsakova. 111:42–45. 2011.(In Russian). PubMed/NCBI
26	Saleem MA, Mukhelif HF, Moussawi KM and Al-Khafaji JT: Human leukocyte antigen typing in Iraqi multiple sclerosis patients. Neurosciences (Riyadh). 12:127–132. 2007.PubMed/NCBI
27	Gough SC and Simmonds MJ: The HLA region and autoimmune disease: Associations and mechanisms of action. Curr Genomics. 8:453–465. 2007. View Article : Google Scholar : PubMed/NCBI
28	Jilek S, Schluep M, Harari A, Canales M, Lysandropoulos A, Zekeridou A, Pantaleo G and Du Pasquier RA: HLA-B7-restricted EBV-specific CD8⁺ T cells are dysregulated in multiple sclerosis. J Immunol. 188:4671–4680. 2012. View Article : Google Scholar : PubMed/NCBI
29	Amirzargar AA, Tabasi A, Khosravi F, Kheradvar A, Rezaei N, Naroueynejad M, Ansaripour B, Moradi B and Nikbin B: Optic neuritis, multiple sclerosis and human leukocyte antigen: Results of a 4-year follow-up study. Eur J Neurol. 12:25–30. 2005. View Article : Google Scholar : PubMed/NCBI
30	Hillert J: Human leukocyte antigen studies in multiple sclerosis. Ann Neurol. 36 Suppl 1:S15–S17. 1994. View Article : Google Scholar : PubMed/NCBI
31	Uría DF: HLA and multiple sclerosis. Studies of a spanish population. Rev Neurol. 31:1066–1070. 2000.PubMed/NCBI
32	Perini P, Tagliaferri C, Belloni M, Biasi G and Gallo P: The HLA-DR13 haplotype is associated with ‘benign’ multiple sclerosis in northeast Italy. Neurology. 57:158–159. 2001. View Article : Google Scholar : PubMed/NCBI
33	Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E, Goodin DS, Pelletier D, Lincoln RR, Bucher P, et al; Multiple Sclerosis Genetics Group, . HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet. 72:710–716. 2003. View Article : Google Scholar : PubMed/NCBI
34	Vasconcelos CC, Fernández O, Leyva L, Thuler LC and Alvarenga RM: Does the DRB1*1501 allele confer more severe and faster progression in primary progressive multiple sclerosis patients? HLA in primary progressive multiple sclerosis. J Neuroimmunol. 214:101–103. 2009. View Article : Google Scholar : PubMed/NCBI
35	Schmidt H, Williamson D and Ashley-Koch A: HLA-DR15 haplotype and multiple sclerosis: A HuGE review. Am J Epidemiol. 165:1097–1109. 2007. View Article : Google Scholar : PubMed/NCBI